98 results about "Urinary protein" patented technology

The invention provides a diabetic nephropathy early warning method, system, equipment and medium, and relates to the technical field of medical data analysis and prediction.The method comprises the steps that multiple urine samples of a user are collected, target urine protein detection is conducted, and multiple urine protein concentrations are obtained; each urine protein concentration is combined with a normal urine protein concentration set to be input into an abnormal data recognition tree, the number of layers of multiple recognition nodes is obtained, and the detection confidence coefficient is obtained through calculation; configuring an abnormal proportion according to the detection confidence coefficient, inputting a plurality of urine protein concentration combination normal urine protein concentration sets into an abnormal data identification tree, deleting urine protein concentrations divided into abnormal data in the abnormal proportion before, and obtaining screened urine protein concentrations; according to the screened urine protein concentration, an auxiliary early warning coefficient is obtained through calculation, and early warning is carried out. The technical problem of low early warning accuracy of diabetic nephropathy in the prior art is solved.

The invention discloses a traditional Chinese medicine compound for reducing urine protein, a traditional Chinese medicine preparation and a preparation method thereof, belongs to the technical field of traditional Chinese medicine compounds, and solves the problems that although the existing western medicine can reduce the urine protein level of a patient to a certain extent, the adverse reaction risk is high; the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-30 parts of prepared rehmannia root, 10-30 parts of Chinese yam, 10-30 parts of dogwood, 10-20 parts of achyranthes root, 5-15 parts of schisandra chinensis, 5-15 parts of semen cuscutae, 10-30 parts of corn stigma, 10-30 parts of rhizoma alismatis, 10-30 parts of astragalus membranaceus, 10-30 parts of fried fructus rosae laevigatae, 10-30 parts of gordon euryale seed, 5-15 parts of flatstem milkvetch seed, 5-30 parts of salvia miltiorrhiza, 3-10 parts of wine-treated rhubarb and 3-5 parts of wine-treated coptis chinensis. According to the traditional Chinese medicine composition, all the medicines are compatible, all the components complement each other, the effects of reducing urinary albumin and protecting the kidney are increased, all the components are reasonably compatible, and the effect of coordinating and synergism is achieved.

The invention belongs to the technical field of molecular biology, and particularly relates to a construction method and application of a streptococcus pneumoniae pneumonia animal model. The invention provides a construction method of a streptococcus pneumoniae infected rat pneumonia and kidney injury model. The method comprises the following steps: S1, applying a streptococcus pneumoniae liquid into the respiratory tract of a rat by adopting an atomization bacterium feeding mode; and S2, verifying whether the rat treated in the step S1 is infected with pneumonia or not and whether kidney injury exists or not. According to the method, whether pneumonia is infected or not is judged by detecting inflammatory factors in alveolar lavage and lung HE staining, and whether kidney injury exists or not is judged by detecting the urine protein / creatinine ratio in a rat urine sample and detecting kidney HE staining. The construction method provided by the invention is convenient to operate, accurate in model construction and high in survival rate.

The invention provides a traditional Chinese medicine composition for treating nephropathy as well as a preparation method and application thereof, and the anti-renal fibrosis effect is remarkably improved by optimizing a leech extraction process and a novel preparation technology. Animal experiments show that urine protein of model animals can be reduced by 67% and serum creatinine can be reduced by 42% after 12 weeks of continuous administration. Clinical tests prove that the traditional Chinese medicine composition has a definite curative effect on IgA nephropathy, membranous nephropathy and the like, and a new choice is provided for treating chronic kidney diseases.

The application belongs to the field of medicine, and particularly relates to application of a Danzhu Fuguan formula in preparation of a drug for treating idiopathic membranous nephropathy (IMN). The Danzhu Fuguan formula comprises the following raw materials in parts by weight: 25-35 parts of Danshen, 10-15 parts of Baizhu, 25-35 parts of Huangqi, 10-20 parts of Jinyinhua, 10-20 parts of Hujiang, 10-20 parts of Yujin, 10-15 parts of Fuling, 25-35 parts of Yiyiren and 10-15 parts of Qianghuo. Research shows that the Danzhu Fuguan formula can effectively reduce the 24-hour urine protein level of IMN patients, and the 24-hour urine protein level shows a significant downward trend with the extension of the treatment course; according to the IMN clinical efficacy standard, the total remission rate of patients receiving the Danzhu Fuguan formula treatment for 3 months is 37%, the total remission rate of patients receiving the treatment for 6 months is 50%, and the total remission rate of patients receiving the treatment for 12 months reaches 72%, and the remission rate increases significantly with the extension of the treatment course.

The invention relates to a urine protein marker for depression and bipolar affective disorder and application of the urine protein marker in early diagnosis. Specifically, the invention relates to application of a reagent for detecting the content of protein in urine of a subject in preparation of a reagent for diagnosing depression and bipolar affective disorder, and the protein in the urine is selected from the following combinations: Uniprot ID: P11766, H7BY57, O95967, O95433, K7ELM9, P15328 and P68371.

The invention provides a portable stable urine protein qualitative detection kit, and relates to the technical field of urine protein qualitative detection. A homogenizing tank is fixedly mounted at the front end in the kit body, a conveying pipe is connected to the middle in the homogenizing tank in a penetrating manner, through holes in an annular array are formed in the surface of the position, located in the homogenizing tank, of the conveying pipe, and a limiting sleeve is fixedly connected to the top of the conveying pipe. A uniform tank is arranged in the kit, a bevel gear and an annular gear are driven by a motor, and a vertical plate at the bottom of the annular gear is driven to rotate in the uniform tank, so that a liquid sample can be fully and uniformly stirred, protein in the sample can be more uniformly distributed, and a detection result can more accurately reflect the actual content of protein in urine; and the detection reliability is improved. The problems that a kit is lack of an effective sample uniform treatment mechanism, if a urine sample is not fully uniform before detection, the protein concentration of a detection part is inconsistent, and the detection result has deviation are solved.

The invention belongs to the technical field of biological medicines, and particularly relates to application and a method of PHF20 in preparation of a medicine for treating systemic lupus erythematosus and the medicine. The invention discloses an application of PHF20 in treatment of systemic lupus erythematosus, a lentivirus with murine PHF20 is selected as a gene therapy tool, an R848 induced lupus mouse model is taken as an experimental subject for gene therapy, and results show that injection of the overexpressed PHF20 lentivirus in a lupus mouse body has the following effects: (1) spleen swelling is improved, and spleen index is significantly reduced; (2) reducing urine protein, urea nitrogen level, anti-dsDNA antibody level and IgG antibody level of the model mouse; and (3) the pathological damage to the kidney of the model mouse is relieved. The research results show that the PHF20 serving as the target provides important reference value for potential application prospects in systemic lupus erythematosus gene therapy and even autoimmune disease gene therapy.

1. The name of the design product: storage (urine protein). 2. The use of the design product: for urine protein detection sample storage. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

This invention provides a physiological age prediction model that predicts the physiological age of a subject by detecting urinary proteins and metabolites in a urine sample. The aforementioned urinary proteins and metabolites are those that change significantly with age, including one or more selected from the following: cartilage intermediate layer protein (CILP2), collagen Alpha 1 chain (COFA1), myristic acid, 12-methyltridecanoic acid, CN family member 5 (CCN5), Sushi domain-containing protein 5 (SUSD5), procollagen C endopeptidase enhancer 1 (PCOLCE), and L-lactate oxidase (LOX), preferably including all of the aforementioned urinary proteins and metabolites.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition and a preparation and application thereof. A compatibility system of monarch, minister, assistant and guide is adopted, rhizoma atractylodis, semen coicis and cortex phellodendri are taken as monarch drugs, polygonum cuspidatum, centella asiatica and fructus kochiae are taken as minister drugs, prepared rheum officinale, radix achyranthis bidentatae and caulis spatholobi are taken as guide drugs, gynostemma pentaphyllum, radix paeoniae alba and rhizoma polygonati are taken as adjuvant drugs, the medicinal materials are compounded according to a specific mass ratio, and the mass ratio of the monarch drugs to the minister drugs to the adjuvant drugs to the guide drugs is (50-80): (50-80): (30-55): (35-70). The traditional Chinese medicine composition provided by the invention can remarkably reduce the levels of blood uric acid, serum creatinine and urea nitrogen, reduce urine protein excretion and improve inflammation, a hypercoagulation state and lipid metabolism disorder, the total effective rate reaches 90%, the adverse reaction is slight, and the recurrence rate is low.

The invention discloses an amniotic epithelial cell-derived exosome for treating gestational hypertension and application thereof, and belongs to the technical field of biological medicines. The exosome (hAECs-exos) is obtained by secreting and extracting human amniotic epithelial cells (hAECs), the particle size distribution of the exosome (hAECs-exos) is 30-150 nm, and the exosome (hAECs-exos) expresses exosome specific markers CD9, CD63 and CD81. The invention also provides a preparation method of the exosome. The preparation method comprises the following steps: isolated culture of hAECs, and ultracentrifugal extraction and identification of the exosome. Animal experiments prove that when the exosome is applied to a gestational hypertension disease model animal in an intravenous injection mode, the blood pressure and urine protein level of the gestational hypertension disease model animal can be remarkably reduced, and the fetal rat dysplasia condition is improved. The invention provides a brand-new and effective biological preparation candidate scheme for the treatment of the gestational hypertension disease.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a kidney-tonifying, mass-eliminating and wind-dispelling prescription for preventing and treating diabetic nephropathy as well as a preparation method and application thereof. The kidney-tonifying, mass-eliminating and wind-dispelling prescription consists of astragalus membranaceus, pseudo-ginseng, caulis spatholobi, honeysuckle stem, rhizoma sparganii, common yam rhizome and gordon euryale seed, the seven medicines supplement one another, and the treatment thought of tonifying qi, nourishing blood, dispelling wind, dredging collaterals, eliminating mass and reinforcing kidney is combined on the basis that'deficiency stasis with rheumatism 'is taken as the core pathogenesis of diabetic nephropathy. The traditional Chinese medicine composition is designed aiming at the common clinical manifestations of diabetic nephropathy, such as urine protein rise, limb numbness, edema and renal hypofunction, plays a role in comprehensive regulation and layered intervention, embodies the innovative concept of combining traditional Chinese medicine syndrome differentiation treatment and modern disease spectrum, and has relatively high industrial value.

The application discloses a liposome curcumin composition for assisting in controlling blood sugar and regulating kidney and application thereof, and belongs to the technical field of food and health food. The composition adopts a modular formula design and comprises a basic active component and an optional kidney protection component. The particle size of the liposome curcumin is accurately controlled to be 60-80 nm, the encapsulation rate is greater than or equal to 80%, the ethanol residue is less than or equal to 0.5 ‰, the gastric juice 2h release rate is less than 33%, and the intestinal juice 2h release rate is greater than 80%. By differentially adjusting the component amount, two scenes of simple blood sugar reduction and blood sugar reduction and kidney protection can be adapted, and bidirectional synergy of stable blood sugar regulation and kidney target maintenance can be realized. The application also provides application of the composition in oral liquid, solid beverage, soft capsule and tablet. It is verified through experiments that the bioavailability of the composition is more than 12 times higher than that of conventional curcumin preparation, the postprandial blood sugar peak value is reduced by 25%-30%, the urinary protein excretion rate is reduced by 18%-22%, the safety and compliance are excellent, and the composition is suitable for industrial production.

The invention discloses a folium cortex eucommiae extract and application of the folium cortex eucommiae extract in prevention and treatment of adriamycin nephropathy, and relates to the technical field of medicines, the folium cortex eucommiae extract is prepared from dried folium cortex eucommiae through water extraction, heating at 65 DEG C, ultrasonic assistance and vacuum freeze drying, LC-MS / MS analysis shows that the folium cortex eucommiae extract contains no less than 200 components, the components mainly comprise flavonoids, terpenes and phenylpropanoids, and the content of the flavonoids, the terpenes and the phenylpropanoids is no less than 100%. The folium cortex eucommiae extract has no obvious cytotoxicity to HK-2 and HBZY-1 cells under the concentration of 0-1500mu g / mL, can be used for preparing medicines for preventing and treating adriamycin nephropathy, inhibits kidney cell apoptosis by down-regulating Bax and up-regulating Bcl-2 and obviously reduces the levels of IL-6, IL-1beta and TNF-alpha in serum, and in an animal model, 150-600mg / kg of the folium cortex eucommiae extract is continuously administrated for 21-30 days in an intragastric manner, so that the effect of preventing and treating adriamycin nephropathy is achieved. The traditional Chinese medicine composition can effectively relieve weight loss, reduce urine protein, serum creatinine and urea nitrogen, increase albumin and improve kidney pathological injury, and is suitable for relieving kidney toxicity in a prophylactic or therapeutic mode in subjects receiving adriamycin chemotherapy.

The invention relates to a method for constructing a preeclampsia prediction model by using clinical laboratory data and a related application thereof. Specifically, the preeclampsia risk prediction model is constructed based on a plurality of clinical indexes of pregnant women, a plurality of clinical laboratory data and insulin growth binding factor binding protein 1 and / or placental growth factors. The clinical laboratory data comprises leukocyte count and / or urine protein, and further comprises any one or combination of platelet count, monocyte proportion, glutamic-straw / glutamic-pyruvic transaminase ratio, glutamyltranspeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Meanwhile, the sensitivity of the prediction model is 88.0% when the specificity of early eclampsia is 85.04% and the sensitivity of the prediction model is 62.5% when the specificity of late eclampsia is 85.04% in a complete independent verification set, and the detection performance of the prediction model is higher than that of the current detection performance.

This invention relates to the field of biomedical technology, and particularly to the application of crotonin A in the preparation of drugs for treating IgA nephropathy. Pharmacodynamic experiments conducted in vivo on a Thy1 rat model showed that crotonin A effectively reduced 24-hour urinary protein and the urinary protein-to-creatinine ratio in an IgA nephropathy model—an anti-Thy1 rat nephritis model—and inhibited the expression of mRNAs of genes related to renal cortical inflammation, proliferation, and fibrosis, including Cyclin E, α-SMA, FN, CCL2, NF-κB, and IL-6, further improving renal pathology. In in vitro cell models, crotonin A inhibited the proliferation of rat mesangial cells and suppressed the expression of mRNAs of TGF-β, Cyclin E, α-SMA, CCL2, NF-κB, and IL-6, indicating that crotonin A has significant anti-inflammatory, anti-cell proliferation, and anti-fibrotic effects. Brucella oleracea has considerable therapeutic potential, providing a potential new drug option for the clinical prevention and treatment of IgA nephropathy, and is of great significance for the development of safe and effective drugs for the treatment of IgA nephropathy.

This invention discloses the application of SNCG protein in the auxiliary diagnosis of prostate cancer, belonging to the field of biomedical technology. The application involves using reagents specifically designed to detect SNCG protein expression in biological samples to prepare products for the auxiliary diagnosis of prostate cancer. Through proteomic analysis of urinary proteins from prostate cancer patients and normal men, this invention revealed that the concentration of SNCG protein in the urine of prostate cancer patients was significantly higher than that in the normal male group. Immunohistochemical analysis of paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue showed that SNCG protein has a certain expression rate in prostate cancer, and that SNCG protein is also expressed in the basal cells of normal prostate glands, indicating a certain relationship between SNCG protein and the occurrence and development of prostate cancer. This invention can be used to assist in the diagnosis of prostate cancer and difficult cases, thereby improving the diagnosis rate and survival rate of patients.

This invention provides a method and storage medium for detecting the pathological type of pulmonary nodules, belonging to the field of medical technology. The method for detecting the pathological type of pulmonary nodules includes: acquiring urinary protein expression profile data of pulmonary nodules from an individual sample to be analyzed; preprocessing the urinary protein expression profile data to obtain standardized data based on a summation of quantitative data; inputting the standardized data into a pre-constructed classifier; and the pre-constructed classifier performing feature matching and prediction on the input data to output the pathological type classification result of the individual sample to be analyzed. This invention addresses the problems of physical harm and psychological burden on patients, as well as inconsistent diagnostic results, caused by traditional methods for detecting the pathological type of pulmonary nodules.

The invention discloses an application of triptophenol terpene in preparation of a medicine for treating diabetic nephropathy, belongs to the technical field of medicines, is obtained by separating and purifying tripterygium glycosides extract, and is applied as a single active component or a core component in DKD treatment medicines, and solves the problems that a traditional tripterygium glycosides preparation is high in toxicity and uncontrollable in curative effect. The medicine of the triptophenol terpene can obviously inhibit kidney inflammatory factors (IL-6 and TNF-alpha) and fibrosis markers (TGF-beta); the urine protein level is reduced, and the kidney function is improved; and hepatotoxicity and reproductive toxicity risks are avoided.

This invention discloses a biomarker, reagent kit, and system for diagnosing bladder injury secondary to benign prostatic hyperplasia (BPH), relating to the field of biomedical detection technology. The biomarker for diagnosing bladder injury secondary to BPH is characterized in that it includes urinary DAB2 protein. This invention achieves (1) clinical applicability: accurate quantitative assessment of the degree of injury. The most significant clinical value of urinary DAB2 protein lies in its ability to transform traditional subjective bladder injury assessment into an objective quantitative indicator. (2) convenient detection: non-invasive and rapid assessment using urine samples. As a urine detection biomarker, urinary DAB2 protein completely changes the traditional bladder injury assessment's reliance on invasive or expensive examinations such as cystoscopy and CT. (3) clinical decision support: the grading diagnostic value of urinary DAB2 protein is directly translated into clinical decision support capabilities, helping to avoid the clinical dilemma of "overtreatment" or "undertreatment."

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating chronic nephritis and a preparation method and application thereof. The traditional Chinese medicine composition for treating chronic nephritis is prepared from the following raw materials in parts by weight: radix angelicae sinensis, roasted rhizoma atractylodis macrocephalae, radix stephaniae tetrandrae, radix saposhnikoviae, poria cocos, herba epimedii, fructus rosae laevigatae, radix astragali and rhizoma curcumae. After a chronic nephritis patient is treated by the traditional Chinese medicine composition, indexes such as serum creatinine and 24-hour urine protein can be remarkably improved, clinical symptoms are remarkably relieved, and a better product is provided for treating the chronic nephritis patient.

The invention discloses a Wilson's disease low-abundance urine protein biomarker detection method, and belongs to the technical field of Wilson's disease, and the method comprises the following steps: S1, collecting a urine sample of a Wilson's disease to-be-detected person, and pre-treating the urine sample; s2, analyzing the pretreated urine sample by adopting a DIA mass spectrometry method, and identifying and quantifying global protein components in the urine sample in an unbiased manner; s3, screening candidate marker proteins significantly related to the Wilson's disease in the global protein components by means of statistics and bioinformatics; and S4, verifying the candidate marker protein obtained by screening through targeted mass spectrometry to obtain biomarker protein data. A DIA mass spectrometry technology is combined with liquid chromatography-ion mobility separation, unbiased deep analysis is carried out on urine proteomes of Wilson disease patients and healthy controls, detection parameters are optimized to improve the number and reliability of protein identification, and potential Wilson disease specific low-abundance protein markers are screened out.

The invention provides a biomarker and a kit for pancreatic cancer screening, and belongs to the technical field of cancer screening. According to the technical scheme, urine proteins of pancreatic cancer patients are screened in a large range, early pancreatic cancer patients are taken as target samples, two specific amino acid fragments are determined, the content of the two specific amino acid fragments in non-pancreatic cancer patients is extremely low, the two specific amino acid fragments are only massively expressed in the patients, and the two specific amino acid fragments can be accurately detected in urine of the early pancreatic cancer patients. Benefited from the specific markers, the invention designs a kit and a detection method for pancreatic cancer screening, according to the method, urine total protein is extracted, enzymolysis, desalination and drying are performed, liquid chromatography-mass spectrometry analysis is performed, and whether a target peak appears on a chromatogram or not is taken as a judgment basis. The screening scheme is high in specificity and sensitivity, simple and convenient to operate, capable of effectively improving the discovery rate of the early pancreatic cancer and good in popularization prospect.

The utility model provides a urine protein collection container, including casing, collection bucket, stirring subassembly and collection mouth. The casing is provided with the hollow inner chamber, is equipped with the door body who can open and close on the casing. The collection bucket is in the inner chamber and can slide out of the casing. The collection bucket upper end is equipped with the liquid inlet, and the liquid inlet is connected with the liquid inlet component. The collection bucket lower end is equipped with the liquid outlet, and the liquid outlet is connected with the liquid outlet component who can open and close. The stirring subassembly is arranged on the collection bucket and one end is inserted into the collection bucket. The collection mouth is set up on the casing and is communicated with the collection bucket by the liquid inlet component, and the collection mouth is provided with the toilet bowl, and the toilet bowl is provided with the splashproof cover or the apron. The urine protein collection container can directly collect urine, and it is more convenient to collect, and it is more beneficial to the detection and preservation of urine.

The invention relates to application of hispidulin or pharmaceutically acceptable salts, esters and solvates thereof in preparation of medicines for treating lupus nephritis. The invention develops a new application of the hispidulin, and proves the treatment effect of the hispidulin on lupus nephritis. Meanwhile, the invention verifies that the hispidulin can obviously improve the renal function indexes (including reducing urine protein, blood urea nitrogen and serum creatinine, increasing serum albumin and improving lipid metabolism) of lupus nephritis, can relieve renal pathological injuries (including reducing glomerular mesangial hyperplasia, basilar membrane thickening, renal tubule dilatation and interstitial inflammation infiltration), and can improve the renal function indexes of lupus nephritis. Kidney immune complex deposition can be reduced (including reduction of deposition of kidney IgG and complement C3), meanwhile, it is found for the first time that angiogenin-like protein 4 (Angptl4) is a key action target for treating lupus nephritis by means of the homospidulin, and the homospidulin plays a kidney protection role by down-regulating Angptl4 expression.

The invention provides application of a composition in preparation of a medicine for treating chronic nephritis, and relates to the field of traditional Chinese medicine preparations. The composition is prepared from the following components in parts by weight: 1 to 4 parts of radix rehmanniae total iridoid glycoside extract, 2 to 6 parts of fructus corni total iridoid glycoside extract and 0.5 to 1.5 parts of fructus corni total triterpene acid extract. The composition shows remarkable drug effects in the aspects of improving the survival state of rats with chronic nephritis, reducing 24-hour urine protein, reducing kidney indexes, reducing hematuria, inhibiting inflammation and the like, and has excellent multiple treatment effects, particularly, the effect of the composition in a specific combination proportion range is equivalent to that of a positive control drug prednisone acetate group, and the composition has good clinical application prospects. And the performance is even better in some indexes.

This invention discloses a method for improving a mouse model of ANCA-associated vasculitis induced by anti-GBM antibodies, relating to the field of animal model construction. The method involves subcutaneously injecting mice with 20 μg rMPO on Day 0; administering 10 μg rMPO on Day 7; subcutaneously injecting 250 μg / kg GCSF daily from Day 11 to 15; and injecting 100 μl of goat anti-GBM serum via the tail vein on Day 16 to obtain the improved mouse model. This method improves the existing anti-GBM antibody-induced ANCA-associated vasculitis mouse model by injecting GCSF. This model enhances the disease severity in ANCA-associated vasculitis mice, specifically reflecting the disease in renal pathology and proteinuria, making the differences more obvious and effectively improving the success rate of model establishment.

The invention provides an application of a BCMA-CD19 bispecific CAR (Chimeric Antigen Receptor)-immune cell in the treatment of membranous nephropathy. Specifically, the invention provides a BCMA-CD19 bispecific CAR or a coding nucleic acid thereof, or a carrier thereof, or an application of a CAR-immune cell thereof, and the BCMA-CD19 bispecific CAR or the coding nucleic acid thereof, or the carrier thereof, or the CAR-immune cell thereof is used for (i) preparing a medicine for preventing and / or treating membranous nephropathy (MN); (ii) preparing a medicine for reducing the urine protein level; (iii) preparing a medicine for reducing the PLA2R antibody titer; (iv) preparing a medicine for improving the serum albumin level; and / or (v) preparing a medicine for improving the renal function eGFR level. The invention also provides a method for reducing urine protein level, reducing PLA2R antibody titer, increasing serum albumin level and / or increasing renal function eGFR level and a method for preventing and / or treating membranous nephropathy (MN) by using the BCMA-CD19 bispecific CAR or a coding nucleic acid thereof, or a carrier thereof, or a CAR-immune cell thereof, or a pharmaceutical composition. The BCMA-CD19 bispecific CAR-immune cell provided by the invention has very good safety and effectiveness, and can achieve the purpose that patients with high-risk, recurrent or refractory membranous nephropathy can continuously obtain clinical deep relief treatment.

The invention discloses a Chinese catalpa fruit-based unilateral preparation for eliminating urine protein and application thereof, and belongs to the technical field of traditional Chinese medicine, the active ingredient of the unilateral preparation is extracted from a single medicinal material of Chinese catalpa fruit, and the unilateral preparation can contain pharmaceutically acceptable auxiliary materials. The single preparation can be prepared into four dosage forms of oral liquid, tablets, dripping pills and granules so as to meet different clinical requirements. Animal experiments prove that the single preparation can effectively eliminate urine protein and improve the renal function through four synergistic mechanisms of anti-inflammation, anti-oxidation, improvement of the renal function, protection of podocyte and immunoregulation and diuresis, and is suitable for treating proteinuria accompanied by nephropathy. The preparation provided by the invention has the characteristics of single formula, easy quality control and various dosage forms, and provides a traditional Chinese medicine scheme with an exact curative effect for clinically treating related diseases.